Analysts predict that Chiasma Inc (NASDAQ:CHMA) will announce earnings per share (EPS) of ($0.33) for the current quarter, according to Zacks. Zero analysts have made estimates for Chiasma’s earnings. Chiasma posted earnings per share of ($0.21) during the same quarter last year, which indicates a negative year-over-year growth rate of 57.1%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 19th.
According to Zacks, analysts expect that Chiasma will report full-year earnings of ($1.28) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will report earnings of ($1.11) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Chiasma.
A number of equities research analysts have recently commented on the company. Roth Capital assumed coverage on Chiasma in a research report on Tuesday. They set a “buy” rating and a $16.00 price objective for the company. HC Wainwright assumed coverage on Chiasma in a research report on Thursday, February 14th. They set a “buy” rating and a $11.00 price objective for the company. Brookline Capital Management reiterated a “buy” rating on shares of Chiasma in a research report on Wednesday, February 6th. Finally, ValuEngine downgraded Chiasma from a “buy” rating to a “hold” rating in a research report on Friday, January 4th.
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Chiasma by 51.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 27,505 shares during the period. Citadel Advisors LLC raised its stake in Chiasma by 100.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 17,881 shares during the period. Renaissance Technologies LLC raised its stake in Chiasma by 20.9% during the 3rd quarter. Renaissance Technologies LLC now owns 82,700 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 14,300 shares during the period. EcoR1 Capital LLC acquired a new stake in Chiasma during the 3rd quarter valued at $1,367,000. Finally, Nexthera Capital LP acquired a new stake in Chiasma during the 3rd quarter valued at $2,292,000. Institutional investors own 61.02% of the company’s stock.
CHMA traded up $0.03 during trading on Thursday, reaching $3.90. The stock had a trading volume of 42,040 shares, compared to its average volume of 34,292. The company has a market capitalization of $96.01 million, a price-to-earnings ratio of -3.68 and a beta of 1.37. Chiasma has a 1-year low of $1.20 and a 1-year high of $4.87.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.